


Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience (NASDAQ:MYGN)























 



Facebook
Google
LinkedIn
Twitter
Email
RSS





Dec 22, 2014



 Previous Release | Next Release 


PDF

Add to Briefcase
File is in Briefcase



Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience
Former Amgen and Eli Lilly Executive Joins Crescendo Leadership Team

SALT LAKE CITY, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of Bernard F. Tobin as president of Crescendo Bioscience, effective January 5, 2015. Mr. Tobin will report to Peter D. Meldrum, president and CEO, Myriad Genetics, Inc., and will succeed William Hagstrom, who has chosen to pursue new start-up business and social venture opportunities. Mr. Hagstrom will remain with the company until January 2, 2015 to ensure a smooth transition in leadership.

	"I want to thank Bill for his outstanding entrepreneurial vision in building Crescendo from the ground up and his leadership through the integration with Myriad to create a world-class diagnostic franchise," said Mr. Meldrum. "I wish Bill and his family the very best."

	"I am grateful to the teams at Crescendo and Myriad for the remarkable opportunity to play a role in building an organization that is improving patients' lives and outcomes in autoimmune diseases," said Mr. Hagstrom. "I am very excited about Crescendo's future and am confident in the company's continued success."

	As the new leader of Crescendo Bioscience, Mr. Tobin will leverage its strong expertise in rheumatoid arthritis (RA) to drive new growth opportunities for Vectra® DA, including obtaining private payer coverage in the United States and expanding the business internationally. In addition, Mr. Tobin will focus on new products from Crescendo's robust pipeline of novel molecular diagnostics for other autoimmune disorders.

	"We are delighted to welcome Bernie to the Crescendo team with his strong experience leading and growing healthcare businesses in the United States and globally," said Mr. Meldrum. "Crescendo is integral to our strategy to further diversify our portfolio and Bernie will assist us in taking Crescendo to the next level. We believe companion diagnostics for autoimmune disorders are one of the fastest-growing and highest-value segments in healthcare today."

	"I look forward to working with the talented management team and employees to ensure that Crescendo is the world leader in molecular diagnostics for autoimmune diseases," said Mr. Tobin. "It is an exciting time to join Myriad, with its commitment to innovation, which will save and improve the lives of patients and help reduce overall healthcare costs."

	Mr. Tobin held several senior positions at Amgen over the past seven years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. Before Amgen, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his bachelor of science degree in public service and administration from Iowa State University in Ames, Iowa, and his master's in business administration from the Fuqua School of Business, Duke University, Durham, N.C.About Crescendo Bioscience

	Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, California. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at: www.CrescendoBio.com.About Myriad Genetics

	Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company's websites: www.myriad.com.

	Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-GSafe Harbor Statement

	This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to new growth opportunities for Vectra DA, obtaining private payer coverage and expanding the business internationally; new products in the Company's pipeline of novel molecular diagnostics for other autoimmune disorders; the importance of Crescendo to Myriad's strategy to further diversify our portfolio; the Company's belief that companion diagnostics for autoimmune disorders are one of the fastest-growing and highest-value segments in healthcare today; and the Company's strategic directives under the caption "About Myriad Genetics." These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will 
not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that 
licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our 
projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the 
heading "Risk Factors" contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.CONTACT: Media Contact:

         Ron Rogers

         (801) 584-3065

         rrogers@myriad.com

         

         Investor Contact:

         Scott Gleason

         (801) 584-1143

         sgleason@myriad.com









 Bernard Tobin – Real Agriculture - Page 6
                 Wheat Wheat481.0000 Soybeans Soybeans1000.7500 Corn Corn374.2500 Canola Canola510.3000 Live Cattle Live Cattl112.9000 Crude Oil WTI Crude Oil 49.7100 Canadian Dollar Canadian D0.8046More MarketsLog InRegisterSubscribeTrendingAppsEventsJobsPromo ClubShop   Author: Bernard TobinBernard Tobin is Real Agriculture's Ontario Field Editor. AgBern was raised on a dairy farm near St. John's, Newfoundland. For the past two decades, he has specialized in agricultural communications. A Ryerson University journalism grad, he kicked off his career with a seven-year stint as Managing Editor and Field Editor for Farm and Country magazine. He has received six Canadian Farm Writers' Federation awards for journalism excellence. He's also worked for two of Canada's leading agricultural communications firms, providing public relations, branding and strategic marketing. Bern also works for Guelph-based Synthesis Agri-Food Network and talks the Real Dirt on Farming. Trusting Cover Crops Pays Dividends Posted March 1, 2016 by Bernard Tobin  Pierceton, Illinois farmer Jamie Scott has been preaching the gospel of cover crops for 10 years. At the recent Innovative Farmers of Ontario annual meeting in London, Scott described how his father was his first and toughest convert. When he told Jim Scott that his idea to plant cover crops on their farm would cost… Read more » Ontario Budget 2016 — Can Agriculture Do More With Less? Posted February 29, 2016 by Bernard Tobin  Ontario’s 2016 budget made many headlines last week – from free university tuition for low income families to a 4.3 cent climate-change-fighting gas tax, and even a lower-than-expected deficit. But what does it all mean for agriculture, farmers and rural Ontario? With some help from our RealAgriculture twitter followers, we peppered Ontario Agriculture, Food and… Read more » Dairy Funding Focuses on Forage and Fat Posted February 4, 2016 by Bernard Tobin  Agriculture and Agri-Food Canada (AAFC) announced Thursday it will spend $1.75 million on research to enhance the energy of forage crops and study the impact dairy products like cheese have on human cardio-vascular health. The investment is part of the Canadian government’s Dairy Research Cluster, which was launched in 2013. As part of the Growing… Read more » Demand Growing for Certified Crop Advisors Posted January 19, 2016 by Bernard Tobin  More than 280 Certified Crop Advisors (CCAs) jammed into a London, Ontario hotel last week to talk agronomy, information and regulation. It was the largest turnout ever for the Ontario Certified Crop Advisors Association annual meeting since the event began 13 years ago. The province currently has 545 active CCAs and the number is expected… Read more » Corn School: Want to Grow 500-Bushel Corn? Stop The Insanity Posted January 8, 2016 by Bernard Tobin  If farmers want to supersize their corn yields, they have to challenge conventional thinking and become students of the crop. That was the main message National Corn Growers Association yield contest champion Randy Dowdy shared with hundreds of farmers at the 2016 SouthWest Agricultural Conference in Ridgetown, Ontario earlier this week. In 2014, Dowdy set… Read more » Dairy Robots — 25 Years Later Posted December 21, 2015 by Bernard Tobin  North America’s first dairy milk robot was installed in 1999, less than 50 kilometres from Jack Rodenburg’s Woodstock, Ontario office. The long-time OMAFRA dairy specialist was sceptical at first, but he quickly realized that robot technology could revolutionize Canadian dairy farms. He says early models had their issues, but he quickly realized the potential for… Read more » Let’s Put Food Cost in Context: Canadians Get a Sweet Deal Posted December 11, 2015 by Bernard Tobin  If you believe the headlines this week, Canadians will soon not be able to afford to eat. Fruit and vegetables will be beyond an ordinary person’s capacity to pay and consumers wanting to chomp down on a piece of meat will have to order horse, bison or ostrich because beef and pork will break their… Read more » Ontario Gets First Flour Mill in 75 years Posted December 8, 2015 by Bernard Tobin  The P&H Milling Group, with support from the Ontario government, is building the first flour mill in Ontario in 75 years. Ontario Minister of Agriculture Jeff Leal made the announcement on Monday at Parrish & Heimbecker’s Hamilton Harbour location, where the new bulk mill is expected to commence operation in 2016. The expansion will allow… Read more » Farm Labour, Health and Safety: How Ontario Works Posted December 7, 2015 by Bernard Tobin  As the Bill 6 debate continues in Alberta, Real Agriculture is taking a look at how other provinces regulate farm labour, health and safety. Are there lessons to be learned from how other provincial legislation was developed and how it’s constructed? Let’s take a look at Ontario. In June 2006, Ontario agriculture was brought under… Read more » Are You Doing Enough to Secure Your Farm? Posted December 4, 2015 by Bernard Tobin  Is your farm secure? That’s a question farmers need to ask themselves says security specialist Larry Wallace. As traditional rural farm communities become more urban, farms become larger and valuable equipment fills yards and drive sheds. That means farmers need to be more diligent in their security practices, says Wallace, who founded Wallace Risk Management… Read more » Tattoos or GMOs? Scenes From the ‘Natural Foods’ Section Posted December 1, 2015 by Bernard Tobin  The “Natural Foods” section of any grocery store is a truly fascinating place. Here you find clusters of people intently reading fine print ingredient labels and sorting through the growing number of label claims fighting for space on product packaging. There’s a little something for everyone – from non-GMO verified, gluten-free, organic and dairy free… Read more » “Different Mood” in Ottawa Benefits Agriculture, says CFA President Posted November 25, 2015 by Bernard Tobin  The Canadian Federation of Agriculture is hoping the arrival of new federal Agriculture Minister Lawrence MacAulay will mark a change in the impact farmers have on public policy. MacAulay’s been on the job for less than a month, but so far Ron Bonnett likes what he sees. The CFA president received a call from the… Read more » Environment and Infrastructure Key Priorities for OFA’s McCabe Posted November 24, 2015 by Bernard Tobin  The Ontario Federation of Agriculture has re-elected Don McCabe as its president for 2016. The Lambton County farmer was unopposed for the position, which he won for the second consecutive year during the OFA’s annual meeting in Toronto this week. Despite being acclaimed, there were some challenges for the returning president regarding how he and… Read more » Dairy Feed Refusals — Waste or the Cost of Doing Business? Posted November 3, 2015 by Bernard Tobin  Every year in the US, feed left in the bunk costs dairy producers $2 billion. That’s about eight percent of all the feed placed in front of dairy cows, says J. W. Schroeder. The North Dakota State Extension Dairy Specialist told a packed presentation room last month at the World Dairy Expo in Madison, Wisconsin,… Read more » Advanced Farm Management Program Helps Farmers Make Better Business Decisions Posted October 19, 2015 by Bernard Tobin  Farming is not just about producing crops or raising livestock. Much of what separates high performance farms from average to below-average farms is their ability to excel at everything from human resources management and looking after their team to understanding financial ratios and how to deal with the banker, says Rob Hannam, lead facilitator for… Read more »                             






Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience - Crescendo Bioscience































































Vectra® DAMyRA®Myriad®myVectra™ 








Facebook
Twitter
Youtube
LinkedIn



























Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience


December 22, 2014


Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience
Former Amgen and Eli Lilly Executive Joins Crescendo Leadership Team
SALT LAKE CITY, Dec. 22, 2014 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of Bernard F. Tobin as president of Crescendo Bioscience, effective January 5, 2015. Mr. Tobin will report to Peter D. Meldrum, president and CEO, Myriad Genetics, Inc., and will succeed William Hagstrom, who has chosen to pursue new start-up business and social venture opportunities. Mr. Hagstrom will remain with the company until January 2, 2015 to ensure a smooth transition in leadership.
“I want to thank Bill for his outstanding entrepreneurial vision in building Crescendo from the ground up and his leadership through the integration with Myriad to create a world-class diagnostic franchise,” said Mr. Meldrum. “I wish Bill and his family the very best.”
“I am grateful to the teams at Crescendo and Myriad for the remarkable opportunity to play a role in building an organization that is improving patients’ lives and outcomes in autoimmune diseases,” said Mr. Hagstrom. “I am very excited about Crescendo’s future and am confident in the company’s continued success.”
As the new leader of Crescendo Bioscience, Mr. Tobin will leverage its strong expertise in rheumatoid arthritis (RA) to drive new growth opportunities for Vectra® DA, including obtaining private payer coverage in the United States and expanding the business internationally. In addition, Mr. Tobin will focus on new products from Crescendo’s robust pipeline of novel molecular diagnostics for other autoimmune disorders.
“We are delighted to welcome Bernie to the Crescendo team with his strong experience leading and growing healthcare businesses in the United States and globally,” said Mr. Meldrum. “Crescendo is integral to our strategy to further diversify our portfolio and Bernie will assist us in taking Crescendo to the next level. We believe companion diagnostics for autoimmune disorders are one of the fastest-growing and highest-value segments in healthcare today.”
“I look forward to working with the talented management team and employees to ensure that Crescendo is the world leader in molecular diagnostics for autoimmune diseases,” said Mr. Tobin. “It is an exciting time to join Myriad, with its commitment to innovation, which will save and improve the lives of patients and help reduce overall healthcare costs.”
Mr. Tobin held several senior positions at Amgen over the past seven years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. Before Amgen, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his bachelor of science degree in public service and administration from Iowa State University in Ames, Iowa, and his master’s in business administration from the Fuqua School of Business, Duke University, Durham, N.C.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, California. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at: www.crescendobio.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company’s websites: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to new growth opportunities for Vectra DA, obtaining private payer coverage and expanding the business internationally; new products in the Company’s pipeline of novel molecular diagnostics for other autoimmune disorders; the importance of Crescendo to Myriad’s strategy to further diversify our portfolio; the Company’s belief that companion diagnostics for autoimmune disorders are one of the fastest-growing and highest-value segments in healthcare today; and the Company’s strategic directives under the caption “About Myriad Genetics.” These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com













 ©2017 Crescendo Bioscience, Inc. All rights reserved. Vectra, Crescendo Bioscience, MyRA and the associated logos are trademarks or registered trademarks of Crescendo Bioscience, Inc. in the United States and other jurisdictions.
Terms & Conditions Privacy Policy















Bernard Tobin - Chesterfield, MO - Company Information









 



























Products
Resources
My Account












Talk to a D&B Advisor 
1-800-280-0780 




Business Directory



MO



Chesterfield



Business Services, Nec



Business Services At Non-commercial Site



                            Bernard Tobin
                                    



 





















B 


Bernard Tobin
CLAIM THIS BUSINESS



14616 ROGUE RIVER DR CHESTERFIELD, MO 63017
Get Directions



(636) 532-4456





Business Info



 Founded 2010
 Incorporated 
 Annual Revenue $89,000.00
 Employee Count 2
 Industries Business Services At Non-commercial Site
 Contacts Bernard Tobin







Contact Business







Your Email Address

Subject:


Message


Send Message





Company Summary


Since 2010, Bernard Tobin has been providing Business Services At Non-commercial Site from Chesterfield. 









VERIFIED Status:
UNVERIFIED



Address:
UNVERIFIED





LAST VERIFIED:

                                    --
                                



Phone:

                                    UNVERIFIED
                                





Payment Method:
UNVERIFIED


view full report





Similar Businesses Nearby


                                        Our similar businesses nearby shows similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Competitive Landscape


                                        Our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Payments Accepted

NO DATA



Hours



                                        Sunday 

                                        

                                                                                            --
                                            
                                        



                                        Monday 

                                        

                                                                                            --
                                            
                                        



                                        Tuesday 

                                        

                                                                                            --
                                            
                                        



                                        Wednesday 

                                        

                                                                                            --
                                            
                                        



                                        Thursday 

                                        

                                                                                            --
                                            
                                        



                                        Friday 

                                        

                                                                                            --
                                            
                                        



                                        Saturday 

                                        

                                                                                            --
                                            
                                        







B

VIEW ADDITIONAL DATA                        
Select from over 115 networks below to view available data about this business. If this data is unavailable or inaccurate and you own or represent this business, click here for more information on how you may be able to correct it. 







Credibility Review





Google





Facebook.com





Yellowbook.com





Bing.com





Yellowpages.com





MerchantCircle





Tele Atlas (TomTom)





Twitter.com





AOL





MapQuest





Yahoo Local





Apple/Siri





Groupon





Hotfrog.com





Comcast.net Search





ReachLocal





Admedia





Dealsplus





Shoptopia.com





Alteryx





Dogtime Media





KSL.com





Sirtune





AmericanTowns.com





Driverside





Kudzu.com





SpecialsAgent.com





Answers.com





eGood





LawInfo.com





spotlikes.com





anywho.com





eGumball





Likeness.com





Spotzot





eServiceLog





MapMyRun





TechnoCom





apartmentguide.com





ezlocal.com





EZToUse.com





Teleroute





AroundMe.com





metropolist.com





Therapists.com





Atlanta NewHomes





FindLaw.com





Time Out New York





Avantar





FindTheBest.com





mojopages.com





B2B Yellowpages





Fivestar Software





MyCityWay.com





TripAdvisor





bckyrd.com





GiftCards.com





MyCoupons.com





beachcalifornia.com





GoLocal247.com





mymove.com





UpMeSocial.com





Belo





GoodInfo





News-Gazette





Nokia





usdirectory.com





Cars.com





Nomao





Centzy.com





hibu





Openlist.com





ChaCha Search





Homeplate.com





OwnLocal.com





VisiKard





challama.com





Homestore





patch.com





Voltari





CityBot





Pelopidas





Vouchd





ClassifiedAds





Hostway





PlaceIQ





WalkScore.com





CloudMade





Hoodoyou





PlanetDiscover.com





WeddingWire.com





PowerProfiles





Where Inc.





Contractors.com





iGoLocal.com





Radiate Media





Wikiocity





CouponMap





Indeed.com





Wimgo.com





CrowdSpot





Innova Electronics





Intellistrand





realtor.com





DataSphere





InTheMO.com





Reply.com





Yellowbot.com





JiWire





Rocket Fuel





YellowPageCity.com





DMV.org





Justclicklocal.com





Dirxion





Keen.com





Zidster.com












Photos














































Business Credit Report
Receive a one-time comprehensive credit report on this company.
get full credit report


Facebook








Twitter








Yelp






































Call 1.800.280.0780 to speak with a D&B Advisor Today!







Customer Resources
Products
Education Center
Business Articles & Insights
Glossary
Contact Us
Customer Support
Communication Preferences
Search for D&B D-U-N-S




Our Company
About Us
Company History
Business Credit History
Careers
Press Releases
News
Success Stories
Hoovers




Our Network
Partners
Affiliates
Blog
Access to Capital
Entrepreneurial Initiative
D&B International
SupplierEdge




Site Links
Business Directory
Site Map
PIPEDA
Privacy Policy
Website Terms of Service
Product License Agreement







© Dun & Bradstreet, Inc. 2017. All rights reserved.

















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft





































Bernard Tobin | GenomeWeb


















Skip to main content



 







 





 









RSS Feeds
Twitter
LinkedIn
 





 







Log in




Join now


 






Business & PolicyBusiness News
Research Funding
Policy & Legislation
Regulatory News
Reimbursement

TechnologyMicroarrays & Multiplexing
PCR
Informatics
Sequencing
Mass Spec
Sample Prep
Gene Silencing/Gene Editing

ResearchGenetic Research
Gene Expression Research
Epigenetics Research
Proteomics & Protein Research
Cell Biology Research

DiagnosticsMolecular Diagnostics
Companion Diagnostics
Biomarker Discovery & Validation
Drug Discovery & Development
Clinical Sequencing
Clinical Proteomics

Disease AreasCancer
Infectious Disease
Cardiovascular Disease
Neurological & Psychological Disease
Metabolic Disease
Autoimmune Disease
Inherited Disease
Reproductive Health

Applied Markets
ResourcesWebinars
White Papers
The Scan
Career Blog
Job Listings
New Products
People in the News
Conferences & Events


Main menu 






Enter your keywords 





 





Home » Resources » People in the News » Bernard Tobin 

















Bernard Tobin

Dec 22, 2014

 



Myriad Genetics has appointed Bernard Tobin as president of Crescendo Bioscience. Tobin joins Myriad from Amgen, where over the past seven years he has held various leadership roles, including executive director of national accounts, general manager of theNetherlandsandBrazil, as well as global head of commercial excellence. Before Amgen, Tobin had worked at Eli Lilly and Co.Tobin will take over for William Hagstrom and report to Myriad CEO Peter Meldrum. Hagstrom has decided to leave Crescendo to pursue startup and social venture opportunities. He will stay with the company until Jan. 2, 2015, and Tobin's appointment will be effective as of Jan. 5.


 



More Like This









Jul 28, 2017


Cynthia Bens

Cynthia Bens will join the Personalized Medicine Coalition as vice president of public policy on August 21. Bens comes to PMC after more than a decade with the Alliance for Aging Research where she helped advocate for policies, including the 21st Century Cures Act, the Prescription Drug User Fee Act, and FDA’s Patient-Focused Drug Development initiative. Prior to that, she spent four years at the bipartisan government affairs firm the Loeffler Group and also worked as a staff assistant on Capitol Hill.


 











Jul 26, 2017


Rohit Khanna

Waters said in a filing with the US Securities and Exchange Commission this week that Rohit Khanna has resigned from his position as SVP, Applied Technology, effective July 21, 2017. Khanna will continue to serve as an SVP of the company and as a member of the firm's executive committee until his retirement on Dec. 31, 2017. 


 











Jul 26, 2017


Scott Howell

Tenet Diagnostics has appointed Scott Howell its CMO. He was most recently executive medical director at Heritage Provider Network. He also continues to practice at Kaiser Permanente Los Angeles Medical Center in the addiction medicine department. He was previously national senior medical director and chief medical officer Network and Population Health, Optim Insight, regional CMO Northeast region of Americhoice, and national medical director of managed care for AIDS Healthcare Foundation. 


 











Jul 26, 2017


Gene DeFelice, Alexandra Snyder

Adaptive Biotechnologies has appointed Gene DeFelice to senior vice president and general counsel and Alexandra Snyder to translational medicine lead for Adaptive Research.DeFelice has served as general counsel for several public healthcare and technology companies, including as primary counsel at Roche Diagnostics. He will join Adaptive's executive team to implement a legal infrastructure for clinical applications of next-generation sequencing technologies.Snyder has joined Adaptive from Memorial Sloan Kettering Cancer Research Center where she specialized in tumor immunogenomics and response to checkpoint blockade immunotherapy.  


 











Jul 24, 2017


Kieran Murphy, Stephen Kanovsky

Kieran Murphy has resigned from the board of NeoGenomics following his appointment as president and CEO of GE Healthcare. NeoGenomics said in a document filed with the US Securities and Exchange Commission that Murphy resigned due to the time demands of his new job, and added that it has appointed Stephen Kanovsky to fill Murphy's position on the board. He is general counsel of GE unit Global Innovation of GE Healthcare.


 











Jul 21, 2017


Thomas Loewald

Thomas Loewald, senior vice president and chief commercial officer at Thermo Fisher Scientific since early 2016, will resign from the company, effective September 1. He joined the firm's Explosives Detection business in 2002 and held various positions over the years, including senior vice president and president of Laboratory Products. Prior to that, he was vice president of sales and marketing for Tyco International.


 











Jul 20, 2017


Mark Stevenson

Mark Stevenson has been promoted to executive vice president and chief operation officer of Thermo Fisher Scientific, effective August 1. In his new role, he will oversee operations of the company's Laboratory Products and Analytical Instruments businesses, in addition to the Life Sciences Solutions business. Since 2014, when Thermo Fisher acquired Life Technologies, Stevenson has been executive vice president and president of Life Sciences Solutions. Prior to that, he was president and chief operating officer of Life Technologies, and before that, he was president and COO of Applied Biosystems.


 











Jul 19, 2017


Hans Bishop

Hans Bishop has been elected to Agilent's board of directors. Bishop is cofounder, president, and CEO of Juno Therapeutics, a Seattle-based biopharmaceutical company. He has also held a range of executive positions in the pharmaceutical industry, including as COO at Dendreon; president of Specialty Medicine at Bayer Healthcare; and global commercial head for Chiron.


 











Jul 19, 2017


Daniel Sikkema

Quanterix has appointed Daniel Sikkema as vice president of acclerator services for the company's new Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development, and clinical sample testing. Sikkema will work to expand the reach of Quanterix's Accelerator Lab services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas. He has previously worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.


 











Jul 17, 2017


Stephen Pereira

Stephen Pereira has been appointed to Immunovia's scientific advisory board. Pereira is a professor of hepatology and gastroenterology at University College London and is an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and the Royal Free Hospital. 


 











Jul 17, 2017


Daniel MacArthur

The American Society of Human Genetics has named Daniel MacArthur as the first recipient of its Early Career Award. He is an assistant professor in the Analytic and Translational Genetics Unit at Massachusetts General Hospital and Harvard Medical School and the co-director of the Medical and Population Genetics Program at the Broad Institute. The new award, which comes with $10,000 in prize money, recognizes contributions of genetics and genomics scientists in the first 10 years of their careers as independent investigators. MacArthur and his colleagues developed the Exome Aggregation Consortium (ExAC) database and website and its successor, the Genome Aggregation Database (gnomAD). He also published many scientific articles on identifying genes associated with rare diseases, in particular muscular disorders.


 











Jul 13, 2017


Mary Thistle

Enterome has appointed Mary Thistle to its board of directors as a non-executive director. Thistle currently serves as chief operating officer at Dimension Therapeutics, and has also served as senior VP of Business Development at Cubist Pharmaceuticals. Prior to joining Dimension in 2015, Thistle held leadership positions at ViaCell. In addition to developing therapeutic products for rare and metabolic liver diseases, Enterome also develops diagnostics to support therapies in microbiome-related diseases such as inflammatory bowel disease and cancer.


 











Jul 12, 2017


Arthur Beaudet

The American Society of Human Genetics has named Arthur Beaudet the recipient of this year's Victor A. McKusick Leadership Award. The award recognizes individuals whose "professional achievements have fostered and enriched the development of human genetics as well as its assimilation into the broader context of science, medicine, and health." Beaudet, who will receive the award along with a $10,000 prize at the ASHG annual meeting in October, is the Henry and Emma Mayer Professor in the Department of Molecular and Human Genetics and the Department of Pediatrics at Baylor College of Medicine. He is a member of the National Academy of Medicine and the National Academy of Sciences and has received several other awards for his work. Beaudet has published more than 350 articles in the scientific literature. 


 











Jul 12, 2017


Kári Stefánsson

The American Society of Human Genetics has named Kári Stefánsson the winner of this year's William Allan Award, a prize established in 1961 that recognizes a scientist for "substantial and far-reaching scientific contributions to human genetics." Stefánsson is the founder of Iceland's Decode Genetics, which has conducted a large-scale population genetics research project in Iceland. He has published more than 500 articles in the scientific literature and has received several awards for his work, including the European Society of Human Genetics Award in 2009.


 











Jul 07, 2017


Matthias Raquet

Oneservice, a Swiss company offering complete managed service solutions, consulting, and learning for the life science, diagnostics, and medical device industries, has appointed Matthias Raquet as CEO. Raquet joins Oneservice from Qiagen, where he has worked since 2001, most recently as vice president and head of global service solutions and global customer management. Prior to Qiagen he worked in various management roles at Amersham Pharmacia.


 






 















Breaking News 

  



New England Biolabs, TTP Partner to Provide MDx Development Services  








People in the News: Thomas Loewald, Gene DeFelice, Alexandra Snyder, and More  








In Brief This Week: PerkinElmer, BD, Eurofins Scientific, and More  








OneOme Inks Deal to Offer PGx Test in Canada  








Panel Sequencing Leads to Pathogenic Mutations in Autoinflammatory Cases  








Genetic Technologies Reports A$147K in Cash Receipts for Q4  




 
 





 







The Scan 







Concentration of Rare Disease 

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.



 









Unexpected Findings 

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.



 









Make it a Bit Fuzzy 

Simple de-identification methods can protect information in a database from attackers, a new study suggests.



 









This Week in Science 

In Science this week: approach to visualize chromatin structure in nuclei, and more.



 






 





 











 




What's Popular?



      In Business News    

  



Helix Launches Genomics App Store, but Will Consumers Pay?Premium  








Roche Diagnostics Revenues Up 5 Percent in First Half  








Thermo Fisher Scientific Q2 Revenues Up 10 Percent; Firm Increases 2017 Guidance Again  








Illumina Settles One Patent Dispute With Qiagen; Faces Separate Suit From Columbia, Qiagen   








Illumina Selects Five More Startups for Accelerator Program  




 
 





 





 












Sponsorships 





 





 





 





 





 





 









 






About us
Advertise
Contact
Jobs
Subscribe







Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved. 





 





















	Bernard Tobin, Insurance Agent/Broker at . Insurance professional in Chesterfield, MO





































































































Home
About Us
Membership
Networking
Inbox
Wall
Import Address Book
Photo Albums
Find Other Professionals

Other Resources
Frequently Asked Questions
Spam Whitelist Instructions
Copyright Credit
Logos & Images
The Complete Marketeer
Manage Subscriptions
Unsubscribe from E-mails

Careers - Open Positions
Contact Us
Manage Your Subscriptions
Consumers



Find It
Find A Market
Exclusive Consumer Leads
Find A Job
Find Candidate(s)
Find A Company
Search Blogs
Search Users
Search Industry Articles
Search Discussions/Topics
Find Tools/Products
Insurance News



Jobs
Find A Job
Post A Job
Find Candidate(s)
Articles for Candidates
Articles for Employers
Talent Solutions
ATS (Applicant Tracking)



Forums
Ask Your Peers
Agency Management
Careers & Jobs
Life, Health & Fin Svcs
Marketing
Property & Casualty
Technology & Tools
Using CompleteMarkets
Groups
My Subscribed Groups
All Groups
Manage Your Subscriptions

Manage Your Subscriptions



Education
All Articles
Search The Library
Article Categories
Manage Your Subscriptions



Blogs
Create Your Own Blog
Insurance Professionals
Insurance Marketing
Advertisers
Market Providers
Axis Brokers
Cochrane & Company
Colonial General Insurance Agency

Industry Experts
6th Sense Proposals
21st Century Management
Dr. Jack Nordhaus
Graham Communications
HR That Works
Sound Marketing Inc.

Product & Service Providers
Aged Insurance Leads
The Wedge Group

All Blogs
Manage Your Subscriptions



Tools
Insurance Newsletters
Jobs/Careers
CallTracking
Productivity Tools
Manage Your Subscriptions



Consumers
Get A Quote
Insurance Categories



Advertise
Advertising Solutions
Talent Solutions
Demo/Media Kit
































































































































































































































Create a Free CompleteMarkets AccountLogin to CompleteMarkets













Are you Bernard Tobin?


Claim your user profile and you will be on your way to enhancing your professional profile in minutes!



119 Public Views


121 Member Views


20 Requests For Info.


Claim My Profile















                    x





No Thanks














                Please wait...






















Bernard Tobin
Member Since: October 2015


















12345


0 Reviews - 0 of 5.0





Write your review here. (Required)

Please consider the following:
1. Would you recommend this person?
2. What about this person do you like/dislike?
3. Why did you choose this rating?


Submit This Anonymously

Cancel
Submit










Write a Review





Please authenticate first to post and/or edit reviews.


Connect
Connect






Or 

Fill out the form below to submit the review.





                            First name:







                            Last name:









                            Email:











I am a ...

Client
Peer


Please give star rating (5 highest/1 lowest)



12345


Rating field is required.


Write your review here. (Required)

Please consider the following:
1. Would you recommend this person?
2. What about this person do you like/dislike?
3. Why did you choose this rating?
Please enter text with minimum of 25 characters long.


Submit This Anonymously




Cancel
Submit



















Birthday: February 1931
Gender: Male





0

                            Reputation ?



The higher your score, the more credibility you have as a member of the site. A reputation score is a system calculated score that takes the following factors into consideration: 

Your profile completeness and accuracy (including pictures)
Your connections and followers
Your activity on blogs, discussions, groups.
How others rate your content, contributions, answers to questions.
Your expertise in your field - other users can rate your responses and that affects your overall reputation score.
The value and frequency of your contributions to the member community.











Insurance Agent/Broker

in Chesterfield, Missouri







                                    Public Profile: 
                                    https://completemarkets.com/BernardTobin/




 Bernard is 85 and has been practicing insurance for at least 1 year/s.  Bernard has been an active member of our network of insurance professionals for 1 year/s.  Bernard has 0 reviews and recommendations from industry peers, insurance clients and/or prospects.
                                




Follow
21




The person you selected will have to confirm your request. You may add a personal message:















Fill out the form below to follow Bernard Tobin.





                            First name:







                            Last name:









                            Email:









Follow





You are now following Bernard Tobin.






You are already following Bernard Tobin.

Unfollow


























            Please wait...












About MeCareer HistoryContentConnectionsReviews










Claim My Profile
















Contact:


Bernard Tobin





Phone:


636-532-4456





Address:


14616 Rogue River Dr, Chesterfield, MO, 63017, USA











Time Zone:


UTC





Languages Spoken:


English














Be the first to write a client testimonial or peer review!






Please login to leave a comment.


Connect


Connect






Sorry, you are not authorized to leave a comment on this review. Only the owner of the profile or the reviewer can leave a comment on this review.














12345






Rating history (Content is rated 0.00 of 0 vote(s).)
Shows who have rated the content, and the rating score.







(0)





12345






Rating history (Content is rated 0.00 of 0 vote(s).)
Shows who have rated the content, and the rating score.







(0)





12345






Rating history (Content is rated 0.00 of 0 vote(s).)
Shows who have rated the content, and the rating score.







(0)





12345






Rating history (Content is rated 0.00 of 0 vote(s).)
Shows who have rated the content, and the rating score.







(0)





12345






Rating history (Content is rated 0.00 of 0 vote(s).)
Shows who have rated the content, and the rating score.







(0)



Write a Review





Please authenticate first to post and/or edit reviews.


Connect
Connect






Or 

Fill out the form below to submit the review.





                            First name:







                            Last name:









                            Email:











I am a ...

Client
Peer


Please give star rating (5 highest/1 lowest)



12345


Rating field is required.


Write your review here. (Required)

Please consider the following:
1. Would you recommend this person?
2. What about this person do you like/dislike?
3. Why did you choose this rating?
Please enter text with minimum of 25 characters long.


Submit This Anonymously




Cancel
Submit





















Most helpful positive review:












None of the reviews have been marked helpful.



Most helpful negative review:












None of the reviews have been marked not helpful.








News Feed


											
            
            
            Currently there are no messages on Bernard Tobin's wall.
            






            Please wait...









            Please wait...










Please wait...















Site Membership




Click here to log in


No account? Register here!
Home
About Us
Privacy Policy
Terms Of Use
User Content Agreement
Copyright Compliance Policy
Contact Us






                                Insurance Pros

Leverage CompleteMarkets
Get A Custom URL
Feedback
Articles






                                Find It

Markets / Products / Services
Blogs / Groups
Other Professionals
Breaking Advertiser News
Jobs/Careers






                                Networking

Inbox
Import Address Book
Import LinkedIn Contacts
Blogs
Groups
Discussions
Photo Albums






                                Advertisers

Why CompleteMarkets?
Get A Custom URL
Testimonials






                                Resources

Frequently Asked Questions
Insurance/Service Providers
Storefronts
Spam Whitelist Instructions









                     
            Copyright
            ©. All Rights Reserved. 
                    INSOMIS Corp.


















 






Bernard Tobin, President, Crescendo Biosciences


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Bernard Tobin



President
at
Crescendo Biosciences


Location: Thousand Oaks, CA





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Bernard Tobin



President
at
Crescendo Biosciences


Location: Thousand Oaks, CA




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Bernard F. Tobin has joined Crescendo Biosciences as President. s the new leader of Crescendo Bioscience, Mr. Tobin will leverage its strong expertise in rheumatoid arthritis (RA) to drive new growth opportunities for Vectra® DA, including obtaining private payer coverage in the United States and expanding the business internationally. In addition, Mr. Tobin will focus on new products from Crescendo’s robust pipeline of novel molecular diagnostics for other autoimmune disorders.
Mr. Tobin held several senior positions at Amgen over the past seven years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. Before Amgen, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his bachelor of science degree in public service and administration from Iowa State University in Ames, Iowa, and his master’s in business administration from the Fuqua School of Business, Duke University, Durham, N.C.



2

Companies in Career





N/A

Related Markets





N/A

Colleagues





N/A

Related Investments








Alias
N/A



Industry
R&D in Biotech, Environmental and various industries (no marketing product yet)




Tags
Leadership, Pharmaceutical Sales, Business Development




Topics of Influence












Web Site







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Bernard TobinCareer (3)






Dec-2014




Crescendo Biosciences



President







Jul-2013 to Dec-2014




Amgen



Global Integration Lead







Jan-2013 to Jun-2013




Amgen



Global Head - Commercial Excellence








Competencies










 Edit
View all 



Bernard TobinEducation (2)






1991



Duke University - The Fuqua School of Business


Marketing






1984



Iowa State University


Public Service and Administration









 Edit



Bernard TobinAchievements and Recognitions





Add Milestone


No milestones has been recorded for Bernard Tobin






 Edit



Bernard TobinLinks





Add Link


No links has been recorded for Bernard Tobin









Bernard TobinInvestments/Acquisitions





No investments has been recorded for Bernard Tobin









Bernard TobinInvestments Representing Others





No investment reps has been recorded for Bernard Tobin








Bernard TobinRelated People







View all 
Peers







John Lopes

President of Microcide












View all 



Bernard TobinRecommended Market Profiles








Life Sciences (Kleiner Perkins Caufield & Byers)

10,000 or More employees
58 companies


















Bernard Tobin – Real Agriculture - Page 2
                 Wheat Wheat481.0000 Soybeans Soybeans1000.7500 Corn Corn374.2500 Canola Canola510.3000 Live Cattle Live Cattl112.9000 Crude Oil WTI Crude Oil 49.7100 Canadian Dollar Canadian D0.8046More MarketsLog InRegisterSubscribeTrendingAppsEventsJobsPromo ClubShop   Author: Bernard TobinBernard Tobin is Real Agriculture's Ontario Field Editor. AgBern was raised on a dairy farm near St. John's, Newfoundland. For the past two decades, he has specialized in agricultural communications. A Ryerson University journalism grad, he kicked off his career with a seven-year stint as Managing Editor and Field Editor for Farm and Country magazine. He has received six Canadian Farm Writers' Federation awards for journalism excellence. He's also worked for two of Canada's leading agricultural communications firms, providing public relations, branding and strategic marketing. Bern also works for Guelph-based Synthesis Agri-Food Network and talks the Real Dirt on Farming. Career opportunities are agriculture’s ticket back into the classroom Posted May 29, 2017 by Bernard Tobin  Consumers need to know where their food comes from. Why don’t we have more agriculture in the classroom? Those are recurring conversation themes and questions AgScape executive director Colleen Smith encounters every day. They’re challenges the Ontario agriculture industry has been grappling with since the Ag In The Classroom program was launched 25 years ago…. Read more » More rain means more soybeans for Ontario Posted May 25, 2017 by Bernard Tobin  Ontario corn planting isn’t finished, but it’s probably done. With more rain sweeping across the province – and pushing total spring accumulation to record levels in many areas – it’s unlikely that farmers will be planting corn when things dry out, says Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA) corn lead Ben Rosser…. Read more » Growing agri-food industry shaping Guelph’s OAC programs Posted May 16, 2017 by Bernard Tobin  The agri-food industry needs more highly qualified people, and the University of Guelph’s Ontario Agricultural College (OAC) is looking for ways to help meet the demand. Producing more graduates is both a challenge and tremendous opportunity, says OAC dean Dr. Rene Van Acker. A study released five years ago indicated that there were three jobs… Read more » Watching for ‘Cow Signals’ is time well spent Posted May 15, 2017 by Bernard Tobin  Every time a cow takes a lame step or stands for a long period of time she’s sending a signal. Farmers who read those signals and respond with efforts to improve cow comfort are rewarded with increased cow longevity and more profit in their pocket. That’s the return on investing in Cow Signals, according to Agribrands… Read more » Putting the squeeze on celebrity influence Posted May 3, 2017 by Bernard Tobin  How powerful is popular culture? It has tremendous influence on much of our daily lives, impacting everything from food choices and diets, to exercise, and what products we buy. Many of these choices our those we make to help our families lead healthy lives. Dr. Timothy Caulfield would like to like to see governments, regulators,… Read more » What’s in it for Agriculture? The Liberal Budget Breakdown Posted April 28, 2017 by Bernard Tobin  The Ontario Liberals are spending big, but there’s not a whole lot in the 2017-18 provincial budget for agri-food and rural Ontario. The Liberals are going to balance the budget but they are going to spend more than $140 billion in this fiscal year and push the provincial debt over $300 billion. There’s big money… Read more » Branding Your Farm Can Make a Difference Posted April 10, 2017 by Bernard Tobin  What do consumers think of Canadian farmers? Recent studies tell us that consumers appreciate and respect farmers’ efforts to produce healthy, affordable, safe food for Canadians. But to maintain the strength of the Canadian farm brand and consumers’ trust, farmers must continue to be brand champions for their own farms and their industry, says Len… Read more » Ontario CCAs Taking Lead on 4R Nutrient Management Posted March 31, 2017 by Bernard Tobin  Almost half of North American Certified Crop Advisors (CCAs) holding a new 4R Nutrient Management designation reside in Ontario. That puts Ontario’s crop advisors at the forefront of efforts to help farmers and agriculture improve water quality, environmental stewardship and sustainability, says Ontario Certified Crop Advisor Association executive director Susan Fitzgerald. Earlier this week, the… Read more » Spray Tips Special Edition: Is Your Boom Too High? Posted March 27, 2017 by Bernard Tobin  High or low, the height of your sprayer boom doesn’t really matter. Right? Actually, that’s a myth. Welcome to a new season of Spray Tips Special Edition. In our first episode we find our dynamic duo of Sprayers101.com, Tom Wolf of AgriMetrix, and Jason Deveau of Ontario Ministry of Agriculture, Food and Rural Affairs, bickering over… Read more » Trump Administration Not Capable of Renegotiating NAFTA: David Frum Posted March 23, 2017 by Bernard Tobin  Will Canadians see a renegotiated North American Free Trade Agreement any time soon? Don’t bet on it, says political commentator David Frum. Earlier this week, the editor of The Atlantic and former speech writer for George W. Bush, shared his thoughts on the Donald Trump presidency and possible NAFTA renegotiation at the Grain Farmers of Ontario… Read more » RealAg Bookclub: Being Off Balance on Purpose Posted March 1, 2017 by Bernard Tobin  Are you searching for balance in your daily life? Have you found it? In this edition of the RealAg Bookclub podcast we’ll discuss the challenges of finding life balance with Dan Thurmon, author of Off Balance On Purpose. We find out how Thurmon seeks to free readers from the “balance” dilemma and empowers them to adopt a new approach… Read more » Deere Rolls Out Carbon Fibre Spray Booms Posted February 24, 2017 by Bernard Tobin  Strong, durable and lightweight. Those are the words John Deere is using to describe its new carbon fibre spray booms. John Deere has been working for years on ways to substitute the composite material for the steel and aluminum traditionally used in farm equipment. After years of testing, the new 120- and 132-foot carbon fibre… Read more » World’s Largest Model Farm Expands with 100,000 Toothpicks Posted February 22, 2017 by Bernard Tobin  What would you do with 100,000 toothpicks? The answer is obvious for Tennessee farmers Chase Long and Colby Counce, builders of the world’s largest model farm. They gathered together some friends and worked for a week to turn the toothpicks into harvested cornfields on their 15,000-acre replica. Real Agriculture first featured the model farm when… Read more » Roots Not Iron – Charting a Course to Soil Health Posted February 13, 2017 by Bernard Tobin  Year-round cover crops growing in a three-crop rotation — sounds like a great idea that could create healthier, more productive soils, but can Ontario growers make it work? That’s a question the Thames Valley Soil and Crop Improvement Association and the Heartland Region are trying to determine with its Roots Not Iron project. In this… Read more » Healthy Soil Will Eat Your Underwear Posted February 9, 2017 by Bernard Tobin  How healthy is your soil? If you want to know all you have to do is bury your underwear, says Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA) soil management specialist Adam Hayes. Last summer, Hayes helped members of the Renfrew County Soil and Crop Improvement Association bury underwear in their fields to determine the… Read more »                            